Cancer mucosa antigens: novel immunotherapeutic targets
Cancer mucosa antigens: novel immunotherapeutic targets
复制标题
DOI：
10.1517/14728222.12.6.749
复制
发表时间：
2008-05
影响因子：
5.8
通讯作者：
L. Hong;D. Fan
中科院分区：
文献类型：
--
作者：
L. Hong;D. Fan
背景：由于缺乏特异性靶点和免疫力低下，通过免疫治疗预防和治疗人类癌症一直是困难的。癌粘膜抗原（CMA）可能成为癌症免疫治疗的有吸引力的靶点，这并不奇怪。目的：介绍并讨论CMA的研究现状。方法：我们回顾了一些CMA已被用于增强对癌症的免疫反应的证据，并取得了一些进展。我们设想未来的发展，以确定CMA及其潜在的应用于癌症治疗。结果/结论：CMA可以合理地被认为是免疫治疗的新靶点。应进行更多的研究，以提高免疫治疗在临床试验中的成功率。
Background: Prevention and treatment of human cancer through immunotherapy has been difficult owing to lack of a specific target and poor immunity. It is of no surprise that cancer mucosa antigens (CMAs) may serve as attractive targets for cancer immunotherapy. Objective: To present and discuss the current state of the research on CMAs. Methods: We review the evidence that a number of CMAs have been used to augment immune responses against cancer and that some progress has been made. We envisage future developments toward identifying CMAs and their potential applications to cancer treatment. Results/conclusion: CMAs may reasonably be considered as novel targets for immunotherapy. More investigations should be performed to improve the success of immunotherapy in clinical trials.